

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES December 20, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3462.1019-000		APPLICATION NO. 10/587,966	
	FIRST NAMED INVENTOR Shuji Sakuma		FILING DATE January 31, 2005	
	EXAMINER Unknown		CONFIRMATION NO. Unknown	GROUP Unknown

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION	
					YES	NO
/E.A./	B1	WO 02/41844 A2	05-30-2002	Etex Corporation		
/E.A./	B2	JP 1-51266 B2	11-02-1989	Kabushiki Kaisha Arusu Japan		X
/E.A./	B3	JP 2-200628 A	08-08-1990	Central Glass Co., Ltd.		X
/E.A./	B4	JP 4-112832 A	04-14-1992	Sangi Co., Ltd.		X
/E.A./	B5	JP 6-329557 A	11-29-1994	Meiji Milk Products Co., Ltd.		X
/E.A./	B6	JP 5-255095 A	10-05-1993	Advance Co., Ltd., <i>et al.</i>	X	
	B7					
	B8					
	B9					
	B10					
	B11					
	B12					
	B13					
	B14					
	B15					
	B16					
	B17					
	B18					
	B19					
	B20					

EXAMINER /Ernst Arnold/	DATE CONSIDERED 04/26/2010
-----------------------------------	--------------------------------------

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES December 20, 2007 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3462.1019-000		APPLICATION NO. 10/587,966	
	FIRST NAMED INVENTOR Shuji Sakuma		FILING DATE January 31, 2005	
	EXAMINER Unknown		CONFIRMATION NO. Unknown	GROUP Unknown

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/E.A./	C1	Aoki, H., <i>et al.</i> , "In Vitro Interaction of Carcinostatic Substances Adsorbed on Hydroxyapatite Microcrystals With Cells Derived From Cancers," <i>Transactions of the Materials Research Society of Japan</i> , 15A: 3-9 (1994).
/E.A./	C2	Liu, Z.S., <i>et al.</i> , "Effects of Hydroxyapatite Nanoparticles on Proliferation and Apoptosis of Human Hepatoma BEL-7402 Cells," <i>World J. Gastroenterol</i> , 9(9): 1968-1971 (2003).
/E.A./	C3	Mohri, N., <i>et al.</i> , "Intraperitoneal and Intrathoracic Administration of Hydroxyapatite-Carboplatin (HAp-CBDCA)," <i>Jpn J Cancer Chemother</i> , 26(12): 1791-1793 (1999).
/E.A./	C4	Nakatani, S., <i>et al.</i> , "Fundamental Study on Hyperthermic Chemotherapy Using Adriamycin-Loaded Hydroxyapatite," <i>Jpn J Cancer Chemother</i> , 19(10): 1644-1647 (1992).
	C5	
	C6	
	C7	
	C8	
	C9	
	C10	
	C11	
	C12	
	C13	
	C14	
	C15	
	C16	
	C17	

EXAMINER /Ernst Arnold/	DATE CONSIDERED 04/26/2010
------------------------------	-------------------------------